ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia

被引：0
|
作者：
Xiang Zhang
Jie Jin
Wenjuan Yu
机构：
[1] Zhejiang University College of Medicine,Department of Hematology, The First Affiliated Hospital
[2] Zhejiang University,Institute of Hematology
[3] Key Laboratory of Hematologic Malignancies,undefined
[4] Diagnosis and Treatment,undefined
[5] Zhejiang,undefined
来源：
Annals of Hematology | 2019年 / 98卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2621 / 2623
页数：2
相关论文
共 50 条
  • [1] ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia
    Zhang, Xiang
    Jin, Jie
    Yu, Wenjuan
    ANNALS OF HEMATOLOGY, 2019, 98 (11) : 2621 - 2623
  • [2] Frequency and clinical features of ASXL2 gene mutation in acute myeloid leukemia patients with AML1-ETO fusion gene positive
    赵俊霞
    ChinaMedicalAbstracts(InternalMedicine), 2016, 33 (04) : 231 - 232
  • [3] K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)
    Maria J. Carnicer
    Adriana Lasa
    Marcus Buschbeck
    Elena Serrano
    Maite Carricondo
    Salut Brunet
    Anna Aventin
    Jorge Sierra
    Luciano Di Croce
    Josep F. Nomdedeu
    Annals of Hematology, 2008, 87 : 819 - 827
  • [4] K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)
    Carnicer, Maria J.
    Lasa, Adriana
    Buschbeck, Marcus
    Serrano, Elena
    Carricondo, Maite
    Brunet, Salut
    Aventin, Anna
    Sierra, Jorge
    Di Croce, Luciano
    Nomdedeu, Josep F.
    ANNALS OF HEMATOLOGY, 2008, 87 (10) : 819 - 827
  • [5] Clinical Features of Patients with ASXL1 and ASXL2 Mutations in Pediatric Acute Myeloid Leukemia
    Yamato, Genki
    Shiba, Norio
    Yoshida, Kenichi
    Ohki, Kentaro
    Park, Myoung-ja
    Hara, Yusuke
    Tomizawa, Daisuke
    Sotomatsu, Manabu
    Taga, Takashi
    Adachi, Souichi
    Tawa, Akio
    Horibe, Keizo
    Arakawa, Hirokazu
    Ogawa, Seishi
    Hayashi, Yasuhide
    BLOOD, 2014, 124 (21)
  • [6] Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO
    Zhang, Shuling
    Zhou, Wei
    Li, Yanchun
    Yu, Shuili
    Xue, Mingming
    Qiao, Yanhong
    Jian, Jinli
    Liu, Bei
    Wang, Degui
    LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1316 - 1319
  • [7] The Clinical and Biological Characterization of De Novo Acute Myeloid Leukemia (AML) with GATA2 Mutation
    Tien, Feng-Ming
    Chou, Wen-Chien
    Hou, Hsin-An
    Chiu, Yu-Chiao
    Chuang, Eric Y.
    Chen, Chien-Yuan
    Tang, Jih-Luh
    Yao, Ming
    Huang, Shang-Yi
    Ko, Bor-Sheng
    Hsu, Szu-Chun
    Wu, Shang-Ju
    Tsay, Woei
    Tien, Hwei-Fang
    BLOOD, 2015, 126 (23)
  • [8] Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21)
    Duployez, Nicolas
    Micol, Jean-Baptiste
    Boissel, Nicolas
    Petit, Arnaud
    Geffroy, Sandrine
    Bucci, Maxime
    Lapillonne, Helene
    Renneville, Aline
    Leverger, Guy
    Ifrah, Norbert
    Dombret, Herve
    Abdel-Wahab, Omar
    Jourdan, Eric
    Preudhomme, Claude
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 199 - 200
  • [9] ASXL1 Mutations Associated with Cytogenetic Findings in DE NOVO and Secondary Acute Myeloid Leukemia
    Kakosaiou, K.
    Daraki, A.
    Apostolou, P.
    Zachaki, S.
    Pagoni, M.
    Sambani, C.
    Dimitriadis, G.
    Papa, V.
    Manola, K. N.
    ANNALS OF HEMATOLOGY, 2015, 94 : S80 - S80
  • [10] ASXL1 Mutations Associated with Cytogenetic Findings in DE NOVO and Secondary Acute Myeloid Leukemia
    Kakosaiou, K.
    Daraki, A.
    Apostolou, P.
    Zachaki, S.
    Pagoni, M.
    Sambani, C.
    Dimitriadis, G.
    Papa, V.
    Manola, K. N.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 80 - 80
12345